A New Era for Food Safety: Codex Alimentarius Adopts Global Guidance on Gluten Labeling

In a landmark decision that promises to reshape how food products are labeled worldwide, the FAO/WHO Codex Alimentarius Commission has officially adopted new international guidance for Precautionary Allergen Labeling (PAL). This move, finalized in July 2026, marks the first time a specific, science-based "reference dose" for gluten has been integrated into global food safety protocols. For the millions of individuals living with celiac disease, this development represents a significant shift from ambiguous, inconsistent warning labels toward a standardized, risk-based framework.

While the long-standing international standard of 20 parts per million (ppm) for "gluten-free" labeling remains firmly in place, the new guidance addresses the often confusing landscape of "may contain" statements. By anchoring these statements in clinical science rather than arbitrary manufacturer policy, the Codex Commission is setting a global benchmark that the Celiac Disease Foundation (CDF) and its international partners hope will soon influence food safety regulations within the United States.

---

The Core Facts: What the New Guidance Changes

For years, consumers with celiac disease have navigated a marketplace cluttered with vague warnings. Phrases like "processed in a facility that also processes wheat" or "may contain wheat" were often used by manufacturers as a legal shield, regardless of the actual level of cross-contact risk.

The new Codex guidance introduces a critical scientific instrument: the 4 mg gluten reference dose. It is vital to clarify that this dose is not a new "gluten-free" threshold, nor is it a target for food manufacturers to aim for in their final products. Instead, it is a tool for professional risk assessment.

Key Takeaways of the Adoption:

• A Shift to Celiac-Specific Science: Previous labeling guidance was primarily derived from wheat allergy standards. The new protocols acknowledge that celiac disease requires an evaluation of cumulative, long-term exposure to gluten derived from wheat, barley, and rye.
• The 4 mg Reference Dose: This is the scientifically derived amount of gluten that, if exceeded, triggers the need for a precautionary label. It allows manufacturers to calculate an "action level"—a specific limit based on the typical serving size of a food product.
• Standardizing "May Contain": The goal is to move away from vague "facility" warnings toward labels that only appear when a genuine, unpreventable risk exists. This helps preserve consumer trust and ensures that those with celiac disease are not unnecessarily restricting their diets due to poorly communicated risks.

---

Chronology of Advocacy: A Multi-Year Effort

The adoption of this guidance was not a sudden regulatory change; it was the result of nearly a decade of rigorous scientific advocacy and international coalition-building.

• 2018: The Celiac Disease Foundation begins its tenure as the North American representative to the Association of European Coeliac Societies (AOECS), laying the groundwork for a unified global approach to gluten safety.
• 2024: Following years of planning, the Celiac Disease Foundation intensifies its efforts to ensure that gluten is treated as a distinct risk category within the Codex framework.
• 2025: The Foundation successfully pushes for the inclusion of gluten experts in FAO/WHO scientific consultations. Simultaneously, the International Society for the Study of Celiac Disease (ISSCD) convenes the Gluten Safety Standards Committee (GSSC) to provide the clinical data required to support a reference dose.
• May 2026 (CCFL48/49): The Codex Committee on Food Labelling (CCFL) holds its 49th session in Ottawa. Celiac Disease Foundation CEO Marilyn Geller represents the community, advocating for the inclusion of the 4 mg reference dose in the final PAL guidance.
• July 2026: The FAO/WHO Codex Alimentarius Commission officially adopts the guidance, formalizing the new international standard.

---

Supporting Data: Why a Reference Dose Matters

The decision to adopt a 4 mg reference dose is rooted in the physiological reality of celiac disease. Unlike a food allergy, where a reaction is often immediate and acute, celiac disease involves systemic, long-term autoimmune damage.

For many years, the industry relied on "wheat-based" metrics. However, wheat is not the only source of gluten; barley and rye contain proteins that are equally damaging to the celiac patient. By moving to a "gluten" standard rather than a "wheat" standard, the new Codex guidance accounts for the total dietary intake of gluten-containing grains.

The reference dose allows for a sophisticated "action level" calculation. If a specific product has a low likelihood of consumption in large quantities, the risk assessment might result in a different labeling requirement than a staple food consumed daily. This scientific granularity is designed to reduce the "noise" of unnecessary warnings, making labels more meaningful for the consumer.

---

Official Responses and Stakeholder Perspectives

The adoption of the guidance has been met with praise from global health organizations and patient advocacy groups alike.

Marilyn Geller, CEO of the Celiac Disease Foundation, stated:

"This is a triumph of science-based advocacy. For too long, the celiac community has been left to navigate a confusing maze of precautionary labels that often had no basis in clinical reality. By securing a dedicated, science-based reference dose for gluten, we have established a new foundation for transparency that protects the health of millions."

Floris van Overveld, Board Chair of the AOECS, noted:

"Our collaboration with the Celiac Disease Foundation allowed us to present a unified, global front. This guidance proves that international regulatory bodies are capable of evolving to meet the specific, chronic-disease-management needs of the celiac population."

The International Society for the Study of Celiac Disease (ISSCD) also played a pivotal role, providing the clinical validation necessary to convince regulators that a 4 mg threshold was the appropriate level to protect those with the most sensitive intestinal tracts.

---

Implications for the United States

Despite the progress made at the international level, the United States faces a unique set of challenges. Currently, the U.S. lacks a formal, regulated framework for precautionary allergen labeling for any allergen. While consumers frequently encounter "may contain" labels, they are entirely voluntary and unregulated, leading to a "wild west" of food labeling.

The Legislative Gap

The U.S. Food and Drug Administration (FDA) currently mandates the declaration of wheat as a "major allergen" under the Food Allergen Labeling and Consumer Protection Act (FALCPA). However, barley and rye do not carry the same mandatory disclosure requirements. This creates a dangerous oversight where products containing malt, barley-derived flavorings, or yeast extracts may lack clear warnings, even though they are high in gluten.

The Path Forward

The Celiac Disease Foundation is now pivoting its efforts toward the FDA, urging the agency to align domestic policy with the new Codex guidance. Key advocacy goals include:

1. Adoption of the 4 mg Reference Dose: Using the Codex standard as the baseline for any future U.S. PAL regulations.
2. Expanded Disclosure: Requiring that barley and rye ingredients be treated with the same transparency as wheat.
3. Consistency: Ensuring that any new labeling framework does not contradict the existing 20 ppm gluten-free standard, thereby preventing consumer confusion.

---

Conclusion: A Blueprint for the Future

The adoption of the FAO/WHO guidance is not merely a bureaucratic victory; it is a fundamental shift in how the food industry approaches invisible health risks. By moving from a culture of "fear-based" labeling—where companies label everything to avoid litigation—to a culture of "risk-based" labeling, the Codex Commission has provided a blueprint for better consumer safety.

For the millions of Americans living with celiac disease, the road to implementation in the United States remains the next great challenge. The Celiac Disease Foundation, bolstered by its success on the international stage, is now better positioned than ever to demand that the FDA adopt these evidence-based standards. As the global food system moves toward greater transparency, the hope is that these labels will eventually become not just a suggestion, but a reliable, consistent standard that ensures every person with celiac disease can shop with confidence, knowing that their health is protected by the best science available.